Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
As interest in GLP-1 medications continues to grow, pharmacists are also helping answer many of the most common questions surrounding weight management, medication options, coverage, and treatment expectations
Semaglutide is a medication that enhances GLP-1 activity, a hormone involved in the regulation of appetite and insulin production
Your decision to try Semaglutide is backed by the medias recognition of its effectiveness
What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency
Want to learn more about how to optimize your stack
GLP-1 receptor agonists such as Semaglutide and Tirzepatide are now being explored as powerful tools in treating both obesity and binge eating disorder
